Physician profile
J Marcus Downs
NPI 1811922610
$3,834.24
in general payments reported to CMS, 2019-2025
23 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $1,736 · 2021: $57.42 · 2022: $342 · 2023: $148 · 2024: $928 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $775 · Travel and Lodging: $447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $774.96 |
| Travel and Lodging | $447.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,072.47 | 2019-2022 | |
| Thd America, INC. | $938.57 | 2023-2025 | |
| Ethicon US, LLC | $150.84 | 2019-2024 | Echelon Flex |
| Sirtex Medical INC | $116.34 | 2019 | |
| Allergan, INC. | $92.04 | 2019-2022 | |
| Abbvie INC. | $46.29 | 2023-2024 | Strattice Reconstructive Tissue Matrix Bps |
| Davol INC. | $45.77 | 2024 | Phasix Mesh |
| Stryker Corporation | $45.45 | 2020 | |
| Conmed Corporation | $45.45 | 2019 | |
| Innovation Technologies INC | $27.94 | 2023 | Irrisept |
| Axonics, INC. | $25.29 | 2023 | Axonics |
| Shire North American Group INC | $23.91 | 2019 | |
| Tela Bio, INC. | $23.54 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Next Science LLC | $22.58 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.53 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $21.75 | 2024 | Signia |
| Becton, Dickinson and Company | $21.19 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $19.75 | 2024 | Exparel |
| Prescient Surgical | $16.30 | 2019 | |
| Heron Therapeutics, INC. | $16.05 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $15.68 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $13.06 | 2023 | |
| Merck Sharp & Dohme LLC | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw J Downs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.